Status:

TERMINATED

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

Lead Sponsor:

Sorrento Therapeutics, Inc.

Conditions:

Covid19

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are ei...

Detailed Description

Subjects will be randomized 2:2:1 to receive a single dose of COVI-DROPS 10 mg, COVI-DROPS 20 mg or matched placebo in a double-blind manner. Investigational product (COVI-DROPS or matched placebo) wi...

Eligibility Criteria

Inclusion

  • Positive for COVID-19 with any locally approved RT-PCR within 7 days of planned treatment.
  • Either have no COVID-19 symptoms (asymptomatic) or mild illness/symptoms
  • Must be willing and able to comply with all planned study procedures and be available for all in-person and telephonic study visits and follow-up as required per protocol
  • Subject must have provided written informed consent
  • Willing to follow contraception guidelines

Exclusion

  • Moderate or severe illness/symptoms or rapidly progressive symptoms which are likely to progress such that a hospitalization is imminent (within 24-48 hours)
  • Any medical condition that, in the Investigator's opinion, could adversely impact subject safety or key objectives of the study, including any intranasal pathology, or clinically significant laboratory abnormalities, or active clinical disease process
  • Documented acute infection other thand COVID-19
  • Pregnant or lactating women who are breast feeding or planning to during the study
  • Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, mAbs against SARS-CoV-2, or intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

Key Trial Info

Start Date :

July 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 6 2022

Estimated Enrollment :

179 Patients enrolled

Trial Details

Trial ID

NCT04900428

Start Date

July 16 2021

End Date

May 6 2022

Last Update

January 30 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals of Coventry and Warwickshire Hospital Trust

Coventry, United Kingdom